Our groundbreaking science is looking at the role of the gut-brain-endocannabinoid axis in profound autism and we are investigating if our drug, KT-20610 can improve both behavioural and gastrointestinal symptoms in ASD.
We are a team of leading experts in the pharmaceutical industry, pharmaceutical development, the science of cannabinoids, healthcare, and pharmaceutical intellectual property who are working alongside representatives from our target patient community.
Kingdom Therapeutics, a clinical-stage biotech specialising in autism and neurodevelopmental treatments, has announced, post the J.P. Morgan Healthcare Conference, that they have selected Novotech, Asia-Pacific’s
Kingdom Therapeutics Ltd, a clinical-stage pharmaceutical company dedicated to developing proprietary therapeutics that modulate the gut-brain-endocannabinoid axis, today announced it has completed a positive pre-IND
Kingdom Therapeutics’ Scientific Advisor, Professor Trevor Jones, recently discussed the significant opportunity for the UK to become a global leader in cannabinoid pharmaceutical development in